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BACKGROUND: There is great need for the development of
highly accurate cost effective technologies that could fa-
cilitate the widespread adoption of noninvasive prenatal
testing (NIPT).
METHODS: We developed an assay based on the targeted
analysis of cell-free DNA for the detection of fetal aneu-
ploidies of chromosomes 21, 18, and 13. This method
enabled the capture and analysis of selected genomic re-
gions of interest. An advanced fetal fraction estimation
and aneuploidy determination algorithm was also devel-
oped. This assay allowed for accurate counting and as-
sessment of chromosomal regions of interest. The analyt-
ical performance of the assay was evaluated in a blind
study of 631 samples derived from pregnancies of at least
10 weeks of gestation that had also undergone invasive
testing.
RESULTS: Our blind study exhibited 100% diagnostic
sensitivity and specificity and correctly classified 52/52
(95% CI, 93.2%–100%) cases of trisomy 21, 16/16
(95% CI, 79.4%–100%) cases of trisomy 18, 5/5 (95%
CI, 47.8%–100%) cases of trisomy 13, and 538/538
(95%CI, 99.3%–100%) normal cases. The test also cor-
rectly identified fetal sex in all cases (95% CI, 99.4%–
100%). One sample failed prespecified assay quality con-
trol criteria, and 19 samples were nonreportable because
of low fetal fraction.
CONCLUSIONS: The extent to which free fetal DNA test-
ing can be applied as a universal screening tool for tri-
somy 21, 18, and 13 depends mainly on assay accuracy
and cost. Cell-free DNA analysis of targeted genomic
regions in maternal plasma enables accurate and cost-
effective noninvasive fetal aneuploidy detection, which is
critical for widespread adoption of NIPT.
© 2016 American Association for Clinical Chemistry
The discovery of free fetal DNA (ffDNA)11 in maternal
circulation (1 ) marked the beginning of the noninvasive
prenatal testing (NIPT) era, and allowed the develop-
ment of the first noninvasive prenatal tests. ffDNA has
been successfully used for the determination of fetal sex
and fetal rhesusD status inmaternal plasma (2, 3 ). These
methods have become routine in a number of clinical
laboratories worldwide. However, direct analysis of the
limited amount of ffDNA in the presence of an excess of
maternal DNA presents a great challenge for NIPT.
The percentage of ffDNA in maternal circulation
was originally estimated to be 3%–6% of the total cell
free DNA (4 ). However, recent studies suggest that fetal
fraction can be as high as 10%–20% (5 ). The presence of
such high amounts of maternal DNA in maternal circu-
lation in relation to the limited amount of fetal DNA
poses a major challenge for the quantification of fetal
DNA and the detection of fetal aneuploidies.
Over the last decade a large number of different
methods have been applied to allow the discrimination or
enrichment of ffDNA from circulating maternal DNA
(6 ). TheDNA-based approaches include sequencing and
epigenetics based assays, which focus on the investigation
of the methylation status of fetal DNA either using
sodium bisulfite DNA treatment (7 ), methylation-
sensitive restriction enzymes, or antibodies specific to the
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5-methylcytosine residues of CpG dinucleotides across
the genome (8–10). Alternative approaches have tar-
geted fetal-specific mRNA (11 ) or have focused on the
investigation of fetal-specific proteins (12 ).
The use of next generation sequencing (NGS) tech-
nologies in NIPT has revolutionized the field. In 2008, 2
independent groups demonstrated that NIPT of trisomy
21 (T21) could be achieved using massively parallel shot-
gun sequencing (13, 14 ), ushering in a new era of NIPT
and opening new possibilities for the use of these tech-
nologies in clinical practice. On the basis of these find-
ings, biotechnology companies and independent groups
initiated clinical studies and developed new NIPT tests
(15–21).
More recently, targeted NGS approaches, in which
only specific sequences of interest are used, have been
developed. A single nucleotide polymorphism–based
NGS approach involving multiplex targeted amplifica-
tion and analysis of single nucleotide polymorphisms and
a quantitative NGS approach that uses ligated probes
that are then amplified and sequenced have been de-
scribed (20, 21 ). Targeted approaches have the potential
to increase throughput and reduce cost because they re-
quire substantially less sequencing than whole genome
sequencing approaches.
Nevertheless, the development of even more accu-
rate, cost-effective NIPT methods is greatly needed. In
particular, approaches that can target specific sequences
of interest, thereby reducing the amount of sequencing
needed compared to whole genome–based approaches,
can be extremely advantageous. Here we present a highly
accurate and cost-effective method for the detection of
fetal trisomies 21, 18, and 13, which overcomes many of
the limitations of the current NIPT technologies.
Materials and Methods
SAMPLE COLLECTION
Plasma samples were obtained anonymously from preg-
nant women of at least 18 years of age from the 10th week
of gestation. Only singleton pregnancies were analyzed.
Protocols used for sample collection were approved by
the National Bioethics Committees and informed con-
sent was obtained from all participants. Referring centers
were provided with all relevant information about eligi-
bility criteria, benefits, and limitations of participating in
this study (22 ). The aneuploid cases enrolled in this
study consisted of T21, trisomy 18 (T18), and trisomy
13 (T13) pregnancies, which were confirmed via invasive
testing.
SAMPLE COLLECTION AND PREPARATION
A mean of 8 mL of peripheral blood was collected from
each subject into EDTA-containing tubes. A mean of
4 mL of plasma was isolated via a double centrifugation
protocol of 1600 g for 10 min, followed by 16 000
g for 10 min. Plasma samples were given a unique iden-
tifier and were stored at80 °C until subsequent analy-
sis. ffDNA was extracted from 4 mL plasma using the
Qiasymphony DSP Virus/Pathogen Midi Kit (Qiagen).
SEQUENCING LIBRARY PREPARATION
Extracted DNA was processed using standard library
preparation methods with minor modifications (23 ).
Negative-control libraries were also prepared. In sum-
mary, 5 and 3 overhangs were filled-in using T4 poly-
merase (NEB) and 5 phosphates were attached using T4
polynucleotide kinase (NEB). Reaction products were
purified using the MinElute kit (Qiagen). Subsequently,
sequencing adaptors were ligated to both ends of the
DNA using T4 DNA ligase (NEB), followed by purifica-
tion using the MinElute kit (Qiagen). Nicks were re-
moved in a fill-in reaction using Bst polymerase (NEB)
with subsequent incubation at 65 °C for 25min and then
12 °C for 20 min. Library amplification was performed
using Fusion polymerase (Agilent Technologies) and all
samples were assigned a unique barcode. Sequencing li-
brary products were purified using the MinElute purifi-
cation kit (Qiagen).
DESIGN AND PREPARATION OF TARGET CAPTURE
SEQUENCES
Custom target capture sequences (TACS) of approxi-
mately 250 bp were designed to capture selected loci
on chromosomes 21, 18, 13, and Y (see Table 1 in the
Data Supplement that accompanies the online version
of this article at http://www.clinchem.org/content/
vol62/issue6). The genomic target-loci were selected on
the basis of GC content, distance from repetitive ele-
ments, and absence of surrounding complex genomic
architecture. The TACS were prepared by polymerase
chain reaction using MyTaq polymerase (Bioline) and
primers designed to amplify the target-loci in normal
DNA. Amplicons were verified by agarose gel electro-
phoresis and were purified using standard PCR clean up
kits such as the Qiaquick PCR purification kit (Qiagen)
or the NucleoSpin 96 PCR clean-up kit (Macherey




Normal 538 538 (100%, 99.3–100)
Trisomy 21 52 52 (100%, 93.2–100)
Trisomy 18 16 16 (100%, 79.4–100)
Trisomy 13 5 5 (100%, 47.8–100)
Sex determination 611 611 (100%, 99.4–100)
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Nagel). TACS concentration was measured using the
Nanodrop spectrophotometer (Thermo Scientific).
TACS were pooled equimolarly, and were blunt
ended using the Quick Blunting kit (NEB). Following
purification using the MinElute kit (Qiagen), they were
biotinylated using the Quick Ligation Kit (NEB) and
were purified using the MinElute kit (Qiagen). The
TACS (1500 ng) were then immobilized on streptavidin-
coated magnetic beads (Invitrogen) as previously de-
scribed (24 ).
HYBRIDIZATION
Amplified libraries were mixed with hybridization buffer
(Agilent), blocking agent (Agilent), blocking oligonucle-
otides (25 ), Cot-1 DNA (Invitrogen), and salmon sperm
DNA (Invitrogen). Sequencing library hybridization
mixtures were then denatured at 95 °C for 3 min and
were incubated at 37 °C for 20min before being added to
the biotinylated TACS. The samples were then incu-
bated for 12–48 h at 66 °C and were washed as previ-
ously described (24 ). Captured sequences were eluted by
heating. Eluted sequences were amplified using outer-
bound adaptor primers. Enriched amplified products
were pooled equimolarly and were sequenced on a
MiSeq, NextSeq 500, or Hiseq 2500 sequencing plat-
form (Illumina).
DATA ANALYSIS
Alignment to the human reference genome. Paired-end read
fragments of each sample were processed using the Cut-
adapt software (26 ) to remove adaptor sequences and
poor-quality reads. The remaining sequences were
aligned to the human reference genome build hg19
(UCSC Genome Bioinformatics) using the Burrows-
Wheeler alignment algorithm (27 ). The Picard tools
software suite [Broad Institute (2015) Picard] was used to
remove duplicate read entries and convert aligned reads
to a binary (BAM) file containing uniquely aligned read
entries. Per base read-depth information was retrieved
from this final BAM file using the SAMtools software
suite. Single nucleotide polymorphism information
across the targeted sequences was obtained using the
bcftools suite of functions and the vcfutils.pl script,
which accompany the SAMtools software suite (27 ).
Classification of fetal aneuploidy. The sequencing proce-
dure introduces read-depth discrepancies across many re-
gions of interest. This bias is in part dependent on the
GC-content of each sequenced region (28 ). GC-bias al-
leviation was achieved by estimating each region’s GC
content and subsequently grouping the read-depth of
similar GC-content regions together to create matching
groups. Matching groups from the test chromosome
were compared to the correspondingmatching groups on
the reference chromosomes using 3 statistical tests: a
paired t-test, a bivariate nonparametric bootstrap, and a
stratified permutation test. The score obtained from each
method was used to calculate a weighted sum. To ac-
count for run-to-run bias (29 ), each weighted sum was
normalized by subtracting the run-specific median and
then dividing by a multiple of the empirical standard
deviation of euploid samples. The run-specific median
was calculated from the weighted sums of all samples in a
sequencing run. The theoretical variance of the random
variable denoted by the weighted sum of the 3 methods
was estimated from a training set of 100 euploid samples.
This normalized score was used to estimate the trisomy
risk (tririsk) of each sample. Scores above a specific
threshold were classified as high-risk for trisomy.
Estimation of fetal fraction. A finite (binomial) mixture
model based on Bayesian inference (30 ) was developed
and used to compute the posterior distribution of fetal
DNA fraction using allelic counts at heterozygous loci in
maternal plasma. Three possible informative combina-
tions of maternal/fetal genotypes were used within the
model to identify fetal DNA fraction values that were
strongly supported by the observed data. The posterior
distribution of fetal fraction was calculated using a
Metropolis-Hastings algorithm (31 ). The lower bound
of the 95% credible interval of this posterior probability
distribution was subsequently inferred.
Results
A total of 631 plasma samples were analyzed in this blind
study, including 52 T21, 16 T18, and 5 T13 pregnancies
from women who had undergone invasive procedures
(Fig. 1). One sample did not pass the sequencing library
quality control criteria and was excluded from the analy-
sis. Another 19 samples (14 normal, 3 T18, 2 T13) ex-
hibited an insufficient ffDNA fraction of4% and were
excluded from the analysis. Fig. 2 summarizes the demo-
graphic characteristics of all 631 samples. The median
maternal age was 36 years, the median maternal weight
was 63 kg, and the median gestational age was 16 weeks.
Tririsk scores for T21, T18, and T13 were assigned
to the 611 samples that passed all quality control criteria
(Fig. 3). Samples with a tririsk score exceeding a thresh-
old of 1 were classified by the classification analysis algo-
rithm as trisomic. A posteriori analysis of the validation
data set suggested that this threshold could be as low as
0.91 (see online Supplemental Fig. 1). T21 was detected
in 52/52 cases (95%CI, 93.2% to 100%) (Fig. 3A). T18
was detected in 16/16 cases (95% CI, 79.4% to 100%)
(Fig. 3B) and T13 was detected in 5/5 cases (95% CI,
47.8% to 100%) (Fig. 3C). These results are summarized
in Table 1.
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The fetal fraction distribution of all cases can be
seen in online Supplemental Fig. 2. The mean fetal
fraction of all samples was 10.9% with an SD of 4.1%.
As shown in Fig. 4, there was no association between
fetal fraction and tririsk scores in normal samples
(Pearson correlation test p-values 0.4 for all 3 aneu-
ploidy tests), although there was a clear association
between these variables in trisomic samples. Specifi-
cally, a Pearson correlation test evaluating the associ-
ation between tririsk scores and fetal fraction in T21,
T18, and T13 samples resulted in p-values of 0.0014,
0.0002, and 0.0164 respectively.
Discussion
This study used a targeted assay that employed target
capture sequences and a novel analytical algorithm to
detect fetal trisomies 21, 18, and 13. In a blind validation
study, which included 631 pregnant women of at least 10
weeks of gestation, the assay results exhibited 100% di-
agnostic sensitivity and specificity and correctly classified
52/52 cases of T21, 16/16 cases of T18, and 5/5 cases of
T13, in all samples that passed quality control criteria
(n 611). The test also correctly identified fetal sex in all
cases.
In this study we focused our analysis on chromo-
somes 21, 18, and 13, and determined that an optimized
set of approximately 1500 loci was sufficient to enable
highly accurate fetal aneuploidy detection.We also tested
alternative sets consisting of fewer TACS and/or TACS
of variable GC content. These experiments allowed us to
determine that the most important technical factor af-
fecting the performance of the assay was the number of
TACS on different chromosomes that exhibited similar
GC-content characteristics, thus allowing for more ro-
bust GC-bias correction.We observed that this was more
pronounced on chromosome 18, where 1 T18 sample
was classified as normal when sets of TACS that were not
optimally matched for GC-content were used. These re-
sults indicated that the assay was sensitive to TACS GC-
content differences, and enabled us to construct an opti-
mal set of TACS on chromosomes 21, 18, and 13 that
resulted in the correct classification of all normal and
trisomic cases (Fig. 3).
Our assay employs a robust analysis algorithm that
minimizes random and systemic variation between se-
quencing runs and is sensitive enough to distinguish be-
tween euploid and aneuploid samples. There is a clear
separation between the risk scores of trisomic and dis-
omic samples (Fig. 3), allowing a binary classification
scheme.
The targeted test described here constitutes an inte-
grated assay that incorporates simultaneous determina-
tion of fetal fraction and accurate detection of fetal ane-
uploidies. The algorithm uses a Bayesian approach to
estimate fetal DNA fraction. As such, additional infor-
mation can be easily incorporated into the model. In
addition, instead of inferring a point estimate of fetal
DNA fraction, the algorithm calculates the posterior dis-
tribution of the fetal DNA fraction in each sample. It
subsequently uses the lower bound of the correspond-
ing 95% credible interval to determine whether a sam-
ple has adequate fetal fraction. This conservative ap-
proach of estimating fetal fraction ensures that the
lowest possible fetal fraction of each sample is consid-
ered for classification purposes, thus minimizing the
possibility of incorrect calls that could potentially arise
from low proportions of fetal DNA. This novel fetal
fraction estimation algorithm was also independently
and thoroughly validated using Y-chromosome loci in
male samples. The fetal fraction estimation algorithm
was also tested using nonpregnant samples. The algo-
rithm correctly identified the absence of fetal DNA in
these samples.
This study identified 3 T18 and 2 T13 samples that
had low fetal fraction. This further illustrates the need for
accurate fetal fraction estimation in NIPT to avoid false
negative (FN) results (32 ). The targeted assay described
here is inherently characterized by high depth of sequenc-
ing, which allows highly accurate fetal fraction quantifi-
cation and aneuploidy detection. In the clinical setting it
is of paramount importance that low fetal fraction
Fig. 1. Flow diagram displaying sample information.
Nineteen samples were excluded from the analysis because of
low fetal fraction, and1 samplewas excludedbecause of technical
reasons. The remaining cohort of 611 samples consisted of 538
normal samples, 52 T21 samples, 16 T18 samples, and 5 T13
samples.
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samples are identified so that a redraw sample is requested
for reanalysis.
The current study evaluated samples from multi-
ple centers in the form of a simple streamlined assay
that can be easily implemented in a clinical setting.
Future work will focus mainly on first trimester sam-
ples and low-risk pregnancies, because NIPT tends to
gradually migrate from second to first trimester
screening, and from high to intermediate and low-risk
pregnancies. Our data suggests that this assay will ex-
hibit the same exceptional accuracy in both low and
high risk pregnancies.
The targeted noninvasive prenatal assay described
here has several advantages compared to whole genome
sequencing methods. Whole genome sequencing re-
quires a very large number of reads and only allows the
simultaneous analysis of very few samples. The inher-
ently limited throughput of whole genome methods im-
poses a significant financial and logistical burden. In con-
trast, the targeted method described here uses only
specific genomic regions and significantly reduces the
number of required reads. This results in a dramatic in-
crease in efficiency and a significant reduction in overall
costs. At the same time, the enrichment of only specific
genomic regions allows for optimal GC-bias correction
and enables high enrichment levels, which result in very
accurate aneuploidy detection. The targeted nature of the
assay also ensures extremely high accuracy by enabling
robust fetal fraction estimation and by avoiding copy
number variants or other complex genomic architectural
elements which can cause false positive (FP) or FN results
(33, 34 ).
Although NIPT has major advantages compared to
conventional screening approaches, a number of chal-
lenges remain. It has been noted that feto-placental mo-
saicism can result in discordant findings between NIPT
and fetal karyotyping (35 ). Chromosomal mosaicism in
chorionic villus samples is detected in 1%–2% of cases,
Fig. 2. Tukey boxplots illustrating demographic characteristics of the 631 samples.
The bottom and top of each box represent the interquartile range (IQR) of the described characteristic and the band inside the box represents
the median value. The “whiskers” of each box illustrate the range of data found within 1.5×IQR. Values greater than 1.5×IQR are illustrated
as empty circles.
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and can involve different numerical and structural chro-
mosomal abnormalities and feto-placental lineages (36 ).
True fetal mosaicism (TFM) is confirmed in only 13% of
these cases, whereas in 87% the chromosomal abnormal-
ity is confined to the placenta [confined placental mosa-
icism (CPM)] (37 ). It is known that ffDNA circulating
in maternal plasma originates from apoptosis of the cells
of the outer layers of the placenta, i.e., the cytotropho-
blast and syncytiotrophoblast cells (38 ). Cases of mosa-
icism, in which the chromosomal constitution of the cy-
totrophoblast is different from that of the fetus, are
potential sources of FP and FN results. CPM type I and
III with an abnormal cytotrophoblast and normal amnio-
cytes can cause FP results, whereas TFM type V with a
normal cytotrophoblast and abnormal amniocytes can
cause FN results (36 ). The largest monocentric study
Fig. 3. Tririsk scores of the 611 classified samples.
T21 cases (A) T18 cases (B) and T13 cases (C). Normal samples are shown as empty circles, trisomic samples as black circles.
Fig. 4. Association of fetal fraction with tririsk scores in normal and trisomic samples.
T21 samples (A), T18 samples (B), T13 samples (C). Normal samples of sufficient fetal fraction for analysis are shown as empty circles and
normal samples of insufficient fetal fraction for analysis (<4%) are shown as empty squares. Trisomic samples of sufficient fetal fraction for
analysis are shown as black circles and trisomic samples of insufficient fetal fraction for analysis (<4%) are shown as black squares. Line of best
fit illustrates the lack of association between tririsk score and fetal fraction in normal samples and conversely the presence of association
between tririsk score and fetal fraction in trisomic samples.
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examining chromosomal mosaicism in relation to NIPT
results includes a retrospective audit of 52673 chorionic
villus samples in which cytogenetic analysis of the cy-
totrophoblast (direct) and villus mesenchyme (culture)
was performed, followed by confirmatory amniocentesis
in chorionic villi mosaic cases (36 ). According to this
study the combined FP rate for T13, T18, and T21,
would be 1 in 3006 cases, and the FN rate would be 1 in
107. Because both T13 and T18 pregnancies are highly
likely to have abnormalities detectable by ultrasound in-
vestigation and will spontaneously abort between 12
weeks and term (39 ), the main concern remains for FP
and FN T21 results. Taking into consideration the inci-
dence of T21 in the general population (40 ) and the
incidence of TFM type V (36 ), the number of FN T21
cases is estimated to be approximately 1 in 100 000
NIPTs. Also, assuming that at least 70% CPM is needed
to produce a FP T21 result (36 ), the FP T21 rate would
be approximately 1 in 13 000. Although these figures are
very low, it is important to be aware of the genetic phys-
iology of the placenta and the limitations it imposes on
NIPT when contemplating its integration into safe clin-
ical prenatal care.
A major objective in the field of prenatal testing is
the reduction of the number of unnecessary invasive
procedures. ffDNA testing can significantly reduce
procedure-related losses while maintaining high detec-
tion rates. It provides clinicians and prospective parents
with a powerful tool to help them make informed deci-
sions regarding the need for an invasive procedure, with-
out posing any risk to the pregnancy. The clinical impact
of ffDNA testing has been significant as indicated by its
quick adoption in prenatal care. The extent to which
ffDNA testing can be applied as a universal screening tool
for T21, 18, and 13 depends mainly on assay accuracy,
low number of nonreportable tests, and cost. In this
study we presented the development and validation of a
novel, cost-effective and exceptionally accurate method
forNIPT of aneuploidies of chromosomes 21, 18, and 13
and fetal sex.
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